All In Biotech

Drug Trial Radar · NCT07211542

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-1905 Injection in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 7, 2025

Primary completion

Sep 2026

Study completion Feb 2027

Sponsor

Sponsor type
Industry
First posted
Oct 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

Conditions

  • Moderate-to-severe Atopic Dermatitis

Interventions

  • SHR-1905 InjectionDrug

    SHR-1905 injection.

  • SHR-1905 Injection Blank PreparationDrug

    SHR-1905 injection blank preparation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects whose Eczema Area and Severity Index (EASI) score decreased ≥ 75% compared to the baseline.Time frame: Week 16.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.